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The aggregation of α-synuclein (aSyn) leading to the formation of
Lewy bodies is the defining pathological hallmark of Parkinson’s
disease (PD). Rare familial PD-associated mutations in aSyn render
it aggregation-prone; however, PD patients carrying wild type
(WT) aSyn also have aggregated aSyn in Lewy bodies. The mech-
anisms by which WT aSyn aggregates are unclear. Here, we report
that inflammation can play a role in causing the aggregation of
WT aSyn. We show that activation of the inflammasome with
known stimuli results in the aggregation of aSyn in a neuronal cell
model of PD. The insoluble aggregates are enrichedwith truncated
aSyn as found in Lewy bodies of the PD brain. Inhibition of the
inflammasome enzyme caspase-1 by chemical inhibition or genetic
knockdown with shRNA abated aSyn truncation. In vitro charac-
terization confirmed that caspase-1 directly cleaves aSyn, generat-
ing a highly aggregation-prone species. The truncation-induced
aggregation of aSyn is toxic to neuronal culture, and inhibition
of caspase-1 by shRNA or a specific chemical inhibitor improved
the survival of a neuronal PD cell model. This study provides a
molecular link for the role of inflammation in aSyn aggregation,
and perhaps in the pathogenesis of sporadic PD as well.
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Over the past two decades, studies stimulated by the discov-ery of genetic mutations occurring in familial Parkinson’s
disease (PD) have generated a number of hypotheses concerning
potential mechanisms of PD pathogenesis. Nonetheless, the
causes and mechanism of sporadic PD, which constitutes the
majority of cases, remain unknown.
Before the genetic discoveries, epidemiologic evidence sug-
gested environmental toxins, traumatic brain injury, and viral
infection as potential causes of idiopathic PD (1–7). All of these
insults could cause neural inflammation, a common feature of
PD brains; however, whether neural inflammation contributes to
the etiology of the disease or is part of its effect remained unclear.
Suggestive evidence indicating the involvement of inflammation in
the pathogenesis of PD emerged after an outbreak of encephalitis
lethargica following the 1918 influenza pandemic, which killed
approximately 1 million people and left many survivors with
postencephalitic Parkinsonism (PEP). Affected persons presented
with cardinal symptoms of typical Parkinson’s disease, including
stooped posture, masklike faces, muscular rigidity, and tremorous
extremities. Contemporary cases of viral infection-associated
Parkinsonism are rare, but both epidemiology and patient case
studies indicate that infection-associated PD still occurs today (8–10).
The role of viral infection in the pathogenesis of PD has been
a controversial subject for more than 50 years. Proponents have
pointed out the known close temporal association between in-
fection and PEP, whereas opponents have cited studies that
failed to find any viral remnants in the brains of affected pa-
tients. Moreover, there were no known routes for peripheral
viral migration into the central nervous system (CNS). Recently,
R. Smeyne and coworkers (11) found that in mice, the influenza
virus (H5N1 strain) can travel from the peripheral nervous sys-
tem into the CNS to higher levels of the neuroaxis. Moreover, in
regions infected by the H5N1 virus, they observed aSyn aggre-
gation that persisted long after resolution of the infection. This
observation provides evidence for the involvement of viral in-
fection and also possibly the immune response in generating
aSyn aggregation and, potentially, the pathogenesis of PD (8, 10,
12). The mechanism by which infections cause aSyn aggregation
remains unknown, however.
Several different posttranslational modifications of aSyn have
been proposed to increase its aggregation propensity, including
phosphorylation, ubiquitination, and truncation (13). Among
these modifications, truncation of aSyn is irreversible and most
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strongly associated with PD pathology; that is, truncated aSyn is
always observed in Lewy bodies and generally is not found in
soluble fractions. Various engineered recombinant truncated
forms of aSyn aggregate readily in vitro and form toxic inclusions
when overexpressed in animal models (14–17). Furthermore,
C-terminally truncated aSyn is ubiquitously present in Lewy bodies
of PD brains, and the amount of truncated forms is correlated
with the number and size of Lewy bodies (18, 19), suggesting that
truncation of aSyn might be an early event that renders it more
prone to aggregate into disease-associated conformations. A
number of in vitro studies have investigated this possibility and
have implicated different proteases that theoretically could
truncate aSyn, including neurosin (20), 20S proteasome (21, 22),
calpain-1 (23), matrix metallo-proteases (MMPs) (24), and ca-
thepsin D (25). However, these are general proteases that cleave
proteins, including aSyn, at multiple locations, and some are
extracellular proteases (i.e., neurosin and MMPs); therefore,
their roles in truncating aSyn intracellularly in vivo remain un-
clear. Moreover, none has a mechanism of activation that cor-
relates with the known risk factors for sporadic PD (i.e., head
trauma and other causes of brain inflammation, cholesterol de-
posits, lysosomal or mitochondrial dysfunction, and aging). A
protease that specifically cleaves a C-terminal segment of aSyn
in vitro and in vivo, producing the same fragment observed in
Lewy bodies, has not yet been identified.
Here, we report that activation of an important component of
the innate immune response system, the inflammasome, leads to
the aggregation of aSyn in neuronal cell culture. This aggrega-
tion is caused by truncation of aSyn by the enzymatic component
of the inflammasome, the cysteine protease caspase-1 (also
known as IL-converting enzyme-1, or ICE). The level of toxicity
to neuronal culture is correlated with the level of aSyn truncation
and is rescued by chemical inhibition of caspase-1 or its genetic
knockdown with shRNA. Taken together, our data demonstrate
that activation of the inflammasome by environmental toxins,
oxidative stress, and infection [i.e., bacterial lipopolysaccharide
(LPS)] causes aSyn truncation and aggregation, which are be-
lieved to be associated with the pathogenesis of PD.
Results and Discussion
Activation of the Inflammasome Causes aSyn Aggregation in Neuronal
Cells. Inflammasomes are key parts of the innate immunity system
that respond to pathogen-associated molecular patterns as well as
to host-derived damage-associated molecular patterns, such as
tissue damage after trauma and metabolic stress, leading to pro-
teolytic activation of the proinflammatory cytokines IL-1β and
IL-18 by the cysteine protease caspase-1 (26).
When we treated neuronal BE(2)-M17 cells overexpressing aSyn
(M17-aSyn) with known inflammasome activators, including
nigericin, aluminum potassium sulfate crystals (APSC), bacterial
LPS, and vitamin K3 (menadione), we found that aSyn is more
localized to the plasma membrane in the treated cells, which also
developed aSyn-positive punctate inclusions that resemble the Lewy
bodies found in PD (Fig. 1A). The redistribution of aSyn to the
plasma membrane and formation of punctate structures are strik-
ingly similar to events that occurred in a yeast model of PD (27).
Nigericin, APSC, and LPS are canonical inflammasome acti-
vators. Whether menadione also activates the inflammasome-
associated protease caspase-1 has been less clear. To determine
this, we measured the levels of pro-IL-1β (the natural substrate
of caspase-1) in cells treated with menadione and found signif-
icantly reduced levels in treated cells compared with untreated
control cells (Fig. 1B), as would be expected if the inflammasome
is activated.
Although the appearance of aSyn-positive punctate structures
in the induced cells resembles the neuronal protein aggregates in
PD, they also could simply represent clustering of aSyn onto mem-
branes of microsomes or lipidic droplets. To determine whether
these inclusions are genuine protein aggregates, as found in Lewy
bodies, or are membrane-associated 2D clusters, we extracted the
membrane fractions and nonmembranous inclusions from
Fig. 1. Inflammasome activation leads to aSyn aggregation. (A) Confocal
microscopy images (at 60× magnification) of M17-aSyn cells stained with
anti-aSyn antibodies, showing concentration and punctate aSyn structures at
the plasma membrane in cells treated with various inflammasome activators.
(B) Western blot of pro-IL-1β from M17-aSyn showing that menadione
treatment leads to pro-IL-1β hydrolysis, and thus caspase-1 activation. β-Actin
(actin) was blotted as a loading standard. (C) Western blot of aSyn extracted
from various cellular fractions, showing that the insoluble aggregates (INS)
consist of truncated aSyn (aSynT) and are undetectable in soluble nuclear
(NUC), membrane (MEM), and soluble cytoplasmic (CYT) fractions.
Fig. 2. Inflammasome activation leads to aSyn truncation. (A) Western blot
of aSyn from M17-aSyn cells showing that inflammasome activators, in-
cluding nigericin (NIG), paraquat (PAR), aluminum crystals (ALU), bacterial
lipopolysaccharide (LPS), and menadione (MEN), lead to truncated aSyn
(aSynT). β-Actin (actin) was blotted as a loading standard. The bar graph
shows the intensity of bands corresponding to aSyn and aSynT relative to
β-actin. (B) Western blot of aSyn from M17-aSyn cells showing that the
amount of aSynT increases with an increasing concentration of menadione.
β-Actin (actin) was blotted as a loading standard.
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the menadione-treated cells. We found aSyn mainly in the
detergent-insoluble fraction and barely detectable in the solubi-
lized membrane fraction, indicating that the aSyn inclusions are
likely genuine protein aggregates and not simply membrane-bound
molecules (Fig. 1C).
Activation of the Inflammasome Results in aSyn Truncation. During
our investigation of inflammasome activation and aSyn aggre-
gation, we noticed that the presence of inflammasome activators
produced a truncated fragment of aSyn. To investigate this in
more detail, we treated M17-aSyn cells with various inflamma-
some activators and monitored their effects on aSyn truncation.
We found that all of the activators tested do indeed cause
truncation of aSyn in M17-aSyn cells (Fig. 2A). Activation of the
inflammasome typically results in the conversion of procaspase-1
(a cysteine protease that is an integral component of the inflam-
masome) into active caspase-1; thus, our results suggest the
possibility of activated caspase-1 directly cleaving aSyn into
smaller fragments. Among the foregoing activators, menadi-
one is the least toxic, the most titratable, and shows a dose-
dependent response (Fig. 2B); therefore, we chose it as a
representative activator for subsequent experiments. We se-
lected a range of menadione concentrations of 0–16 μM for
experimentation, because at higher concentrations we ob-
served the presence of SDS-insoluble oligomers or high mo-
lecular weight species.
To determine whether caspase-1 is directly involved in the
cleavage of aSyn, we treated M17-aSyn cells with the caspase-1–
specific inhibitor VX765 and monitored its effects on aSyn
truncation. We found that inhibition of caspase-1 with VX765
significantly reduced the amount of truncated aSyn in the treated
M17-aSyn cells (Fig. 3A). Although VX765 is a potent and
specific caspase-1 inhibitor, to verify that its rescue of aSyn
truncation is not due to off-target effects, we also tested whether
a similar rescue of aSyn truncation would occur when the caspase-1
gene is silenced with shRNA (Fig. S1). Indeed, we found that
knockdown of the caspase-1 gene dramatically reduced aSyn trun-
cation compared with control (Fig. 3B). These results suggest that
caspase-1 directly cleaves aSyn in M17-aSyn cells.
Truncation of aSyn has been shown to correlate with the rate of
formation and the size of Lewy bodies found in brains of patients
with PD (28). To determine whether caspase-1 is present in Lewy
bodies of PD, we isolated Lewy bodies from postmortem PD
brains and stained them with specific antibodies for caspase-1 and
aSyn. We found that the Lewy bodies stained positive for both
caspase-1 and aSyn (Fig. 4), confirming their coexistence in Lewy
bodies and supporting the notion that caspase-1 also might be in-
volved in generating the truncated aSyn found in Lewy bodies.
Caspase-1 Truncates aSyn at Asp121. To further study the activity of
caspase-1 on aSyn in more detail, we investigated the activity of
human recombinant caspase-1, expressed and purified as de-
scribed previously (Fig. S2) (29), with purified recombinant aSyn
as its substrate in an isolated binary in vitro system. We incubated
10 μg of aSyn with increasing concentrations of caspase-1 (0.5, 1,
1.5, 2, and 2.5 μM) and analyzed the proteolyzed product using
both SDS/PAGE and Western blot analysis. We found that the
amount of truncated aSyn increased proportionately with in-
creasing caspase-1 concentration (Fig. 5A), demonstrating that
caspase-1 directly truncates aSyn in vitro. We observed that the
cleavage of aSyn occurred slowly and approached nearly complete
digestion after overnight incubation. Whereas the P1 position of
natural caspase-1 substrates have 100% stringently conserved
amino acid Asp (which we have identified as Asp121 in aSyn), the
cleavage efficiency is determined by the surrounding residues
(P10–P10′). The optimal sequence for caspase-1 is WEHDS/G at
positions P4-P3-P2-P1-P1′, respectively, but the cleavage se-
quence in aSyn is VDPDN; thus, it is not optimal for efficient
cleavage.
To ensure that the truncated fragment of aSyn is generated
specifically by caspase-1 and not by a copurifying impurity, we
treated the proteolysis reaction mixture with a caspase-1–specific
inhibitor NCG00183434 (ML132) (30), and found that ML132
treatment resulted in significant reduction in truncated aSyn
(Fig. 5B), confirming that caspase-1 directly truncates aSyn.
(Note that VX765 was not used for the in vitro experiments
because it is a prodrug that requires cellular esterase activity for
conversion into the active inhibitor.)
To determine precisely where caspase-1 cuts aSyn, we used
matrix-assisted laser desorption/ionization time-of-flight (MALDI-
TOF) mass spectrometry to determine the size of the major
caspase-1–cleaved fragment (Fig. 5 C and D). The truncated
fragment of aSyn was found to have a molecular mass of 13,167 Da,
which corresponds to the molecular mass of an aSyn fragment
ending at residue aspartic acid 121 (theoretical molecular
mass, 13,166 Da). This is consistent with the fact that caspases
Fig. 3. Inflammasome inhibition leads to reduction of aSyn truncation.
(A) Western blot of aSyn from M17-aSyn showing that the specific caspase-1
inhibitor VX765 inhibits aSyn truncation compared with control (CON). The
bar graph shows the intensity of bands corresponding to aSyn and aSynT
relative to β-actin. (B) Western blot of aSyn from M17-aSyn cells transfected
with anti–caspase-1 shRNA and treated with 10 μM menadione (RNAi),
showing that knockdown of caspase-1 expression diminishes aSyn trunca-
tion compared with control (CON).
Fig. 4. Caspase-1 and aSyn in Lewy bodies. Lewy bodies from PD brain
stained with specific antibodies for aSyn (red) and caspase-1 (green), show-
ing the presence of caspase-1 in Lewy bodies.











are aspartic acid-specific enzymes that cleave immediately after
an aspartic acid.
To confirm that we identified the correct cleavage site, we in-
troduced a point mutation substituting Asp121 for glutamic acid,
which we expressed and purified as described previously (31, 32)
(Fig. S3). Introducing the D121E mutation completely abolished
truncation of aSyn by caspase-1 in our in vitro experiments (Fig. 5A,
lane 121E), confirming that caspase-1 does indeed cleave aSyn after
residue D121. We created a construct for the expression of the
D121Emutant in neuronal cells to determine whether this mutation
would ameliorate inflammasome-induced toxicity; however, cells
transfected with the D121E aSyn construct were synthetically lethal.
aSyn Truncation Produces an Aggregation-Prone Species in Vitro.
Lewy bodies consist of various truncated forms of aSyn, and it
has been speculated that the more aggregation-prone truncated
aSyn might first aggregate, forming seeds that then nucleate the
aggregation of full-length aSyn (33, 34). Therefore, we set out to
characterize the aggregation propensity of caspase-1–truncated
aSyn. Full-length aSyn is stable against aggregation for more than
100 h, but we found that aSyn samples predigested with caspase-1
began to aggregate at approximately 30 h, as determined by a
thioflavin-T (ThT) fluorescence aggregation assay, and rapidly
increased to maximum intensity by 40 h (Fig. 6A). This suggests
that caspase-1–truncated aSyn is more aggregation-prone than
the full-length protein. The caspase-1–digested sample presented
in Fig. 5B consisted of only approximately 10% of the truncated
form, based on SDS/PAGE, which would have been insufficient to
generate the large amount of aggregates observed, thus supporting
the notion that truncated aSyn aggregates first and then seeds the
aggregation of full-length aSyn.
To investigate the aggregation propensity of the caspase-1–
truncated aSyn fragment (residues 1–121) by itself, we subcloned,
expressed, and purified the corresponding C-terminal–truncated
construct (aSyn 1–121) using a procedure previously developed for
full-length protein (Fig. S4). In a ThT fluorescence aggregation
assay, the purified aSyn1-121 began to aggregate at approximately
5 h and reached its maximum by 10 h (Fig. 6B), significantly faster
than any of the other forms of aSyn that we tested, including all of
the disease-associated mutants and heat-denatured samples. This
result confirms that caspase-1–truncated aSyn is aggregation-
prone, and implies that caspase-1 activity might directly initiate
aSyn aggregation, leading to Lewy body formation in vivo.
Inhibition of Caspase-1 Rescues Neuronal Cells from aSyn-Induced
Toxicity. To investigate whether the inflammasome-associated
truncation and aggregation of aSyn described above are associated
with the aSyn-induced cytotoxicity believed to be the cause of
neuronal death in PD, we first measured the viability of M17-aSyn
cells in various concentrations of menadione (0–19 μM) and
compared the values with the values of M17 cells transfected with
empty pcDNA vectors. We found that M17-aSyn cells were more
sensitive to menadione toxicity than the control cells (Fig. 7A). At
14 μM, the viability of M17-aSyn was approximately one-half that
of control cultures. The level of toxicity was roughly correlated
with the severity of aSyn aggregation (Fig. 7C).
We next investigated whether inhibiting caspase-1 activity could
rescue these toxic effects of aSyn in 15 μM menadione by com-
paring the viability of M17-aSyn cells with and without the cas-
pase-1 inhibitor VX-765. We found that VX-765 treatment
partially rescued cell viability, from ∼50% viability to ∼65% (Fig.
7B), suggesting that caspase-1 activity might contribute to cellular
toxicity. Although VX-765 is known to be specific for caspase-1, to
rule out unanticipated nonspecific effects, we tested whether a
similar rescuing effect would occur when the expression of cas-
pase-1 is knocked down with shRNA. We found that the silencing
of caspase-1 expression to 30% of WT protein levels with shRNA
(Fig. S1) also partially rescued M17-aSyn cells, from ∼50% via-
bility to ∼70% viability (Fig. 7B).
Conclusions
The PD brain is known to be inflamed (35–37), and IL-1β is
known to be activated in synucleinopathies (38–41); however,
whether neuroinflammation, and thus caspase-1 activation, is the
cause or the consequence of the disease process has remained
unclear. A number of studies have provided evidence supporting
the role of inflammation in the pathogenesis of neurodegenerative
Fig. 6. Truncated aSyn is aggregation-prone. (A) ThT aggregation assay
showing that aSyn sample preincubated with caspase-1 (solid line) is more
aggregation-prone than control (dashed line). (B) ThT aggregation assay
showing that C-terminal–truncated aSyn consisting of residues 1–121 (solid
line) aggregates more readily than full-length aSyn (dashed line).
Fig. 5. Caspase-1 directly cleaves aSyn. (A) SDS/PAGE of purified recombi-
nant aSyn incubated with various concentrations of purified recombinant
caspase-1, showing that a concentration-dependent truncation of aSyn and
D121E mutation (121E) abolishes this activity. The bar graph shows the in-
tensity of bands corresponding to truncated form relative to full-length
aSyn. (B) Western blot of an in vitro aSyn truncation assay showing that the
caspase-1–cleaved aSyn (CA) compared with control lacking caspase-1 (BL)
and inhibitor of caspase-1 ML132 (ML) inhibit aSyn truncation. (C and D)
MALDI-TOF mass spectrum of an in vitro aSyn truncation reaction with cas-
pase-1 (C), showing full-length aSyn (15,366) and a small peak at ∼13 kDa (*),
which, when focused (D), reveals a molecular weight corresponding to a
fragment of aSyn consisting of residues 1–121 (13,167).
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diseases (42, 43). Specifically, known risk factors for PD, including
aging (44), pesticide exposure (45), traumatic brain injury (46),
the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
(47), lysosomal storage diseases (48), and brain infection (49),
can result in the activation of caspase-1. Chemical inhibition of
caspase-1 or its gene deletion was found to rescue mouse models
of PD from MPTP-induced toxicity (50), although the basis for
that rescue was not completely understood. Activation of the
inflammasome with bacterial endotoxin LPS selectively causes
dopaminergic neuron cell death in mice (51). These different
lines of evidence point to caspase-1 activation as a common in-
tersection to disease.
Our results provide a direct association of caspase-1 truncation
of aSyn with aggregation and neuronal cell toxicity, and hence
suggest that inflammation may play an important role in the
pathogenesis of PD, as numerous reports have suggested (8, 9, 52,
53), as well as other neurologic diseases (53–56). Our data suggest
that modulation of caspase-1 activity (or inflammasome activity)
might be an effective strategy for preventing or treating PD. In an
accompanying paper (57), Bezard, Meissner, and colleagues show
that chemical inhibition of caspase-1 mitigates alpha-synuclein
pathology and mediates neuroprotection in a transgenic mouse
model of multiple system atrophy.
Methods
Tissue Culture. The production of stable cell lines overexpressing aSyn from
parental BE(2)-M17 human dopaminergic neuroblastoma cells has been
described elsewhere. Cells were cultured in Opti-MEM (Life Technologies)
supplemented with 10% (vol/vol) FBS and 500 μg/mL G418.
Inflammasome Activation. M17 cells were grown to 90% confluence in me-
dium (Opti-MEM; Invitrogen) containing 10% (vol/vol) FBS (Atlanta Biolog-
icals) and 500 μg/mL G418. The following inflammasome activators (all from
InvivoGen) were added to the culture medium: monosodium urate crystals
(100 μg/mL), LPS from E. coli K12 (LPS-EK) (1 μg/mL), and LPS-EK ultrapure
(1 μg/mL). After incubation at 37 °C in a humidified 5% (vol/vol) CO2 in-
cubator overnight, the cells were harvested for Western blot analysis.
Caspase-1 Activity Assay. Recombined caspase-1 (rCASP) protein activity was
measured using the Caspase-1 Drug Discovery Kit (BML-AK701; Enzo Life Sci-
ences),with an rCASP stock solution concentrationof 0.3mg/mL. Protein samples
(0, 50 U of caspase-1 standard, 5 μL of rCASP, 15 μL of rCASP, 25 μL of rCASP,
150 μL of rCASP) were added to assay buffer [50 mM Hepes (pH 7.4), 100 mM
NaCl, 0.1% CHAPS, 10 mM DTT, 1 mM EDTA, 10% (vol/vol) glycerol], to a total
volume of 50 μL in a 96-well plate. The reaction was initiated by the addition of
50 μL of 100 μMAc-YVAD-7-amino-4-methylcoumarin (AMC) as a substrate, and
fluorescence was read (excitation wavelength, 360 nm; emission wavelength,
460 nm) continuously at 30 °C in 1-min intervals for a total of 30 min using a
FlexStation2 fluorescence plate reader (Molecular Devices). The standard curve
for fluorescence vs. AMC concentration was constructed by measuring the
fluorescence emitted from various concentrations of AMC at 30 °C.
Caspase-1 activity on aSyn was conducted similarly; however, 10 μg of aSyn
and 50 nM caspase-1 were incubated at 30 °C for 30 min and then analyzed by
Western blot analysis (as described above) and MALDI-TOF mass spectrometry.
For mass spectrometry analysis of caspase-1 truncated aSyn, 1 μL of sample
was spotted on aMALDI target containing 1 μL of matrix and 10mg/mL sinapic
acid, and analyzed on an AB SCIEX 5800 TOF/TOF mass spectrometer (Applied
Biosystems).
ThT Aggregation Assay. Protein samples (full-length WT, full-length WT with
2 μM caspase 1, 90% full-length and 10% truncated form, truncated form)
were added to 100 μL of 100 mM Hepes (pH 7.4), 150 mM NaCl, 10% (vol/vol)
glycerol, 0.1% BOG, and 5 μM ThT to reach a final concentration of 0.2 mM,
followed by incubation at 37 °C with frequent agitation. The fluorescence of
the ThT (excitation wavelength, 440 nm; emission wavelength, 490 nm; cutoff
wavelength, 475 nm) was measured with a FlexStationII scanner (Molecular
Devices) at 37 °C in 1-h intervals over a 1-wk period.
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